Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

REG-ABCAM Plc Director/PDMR Shareholding

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091006:RnsF3221A
                                                                                                                       .
RNS Number : 3221A  
  
ABCAM Plc  
  
06 October 2009  
  
Abcam plc ("Abcam" or "the Company")   
  
PDMR Dealings   
  
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that 
markets antibodies via its own online catalogue, announces that on 5 October 
2009 Jane Cooke, a PDMR of the Company, sold 5,000 ordinary shares of 1 pence 
each in the Company at a price of 875p per ordinary share. Following this 
transaction Mrs Cooke has an interest in 349 ordinary shares under the Company's 
share incentive plan and has options over 17,794 ordinary shares under the Abcam 
plc 2005 Plan which vest subject to specific performance criteria and options 
over 3,375 ordinary shares under the Abcam SAYE Scheme 2006.  
  
 
  Abcam                                               + 44 (0) 1223 696000   
                                                                             
                                                                             
  Jonathan Milner, Chief Executive Officer                                   
  Jeffrey Iliffe, Chief Financial Officer                                    
                                                                             
  Numis Securities                                    + 44 (0) 20 7260 1000  
                                                                             
                                                                             
  Michael Meade / Nick Westlake, Nominated Adviser                           
  James Black, Corporate Broking                                             
                                                                             
  Buchanan Communications                             + 44 (0) 20 7466 5000  
                                                                             
                                                                             
  Mark Court/ Stasa Filiplic                                                 
  
  
Notes for editors:   
  
About Abcam plc   
  
Abcam is a producer and distributor of research-grade antibodies headquartered 
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, 
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and 
trades under the ticker symbol ABC. The Company produces and distributes its own 
and third-party produced antibodies to academic and commercial users throughout 
the world. Product ordering is available through the Company's website 
www.abcam.com, where customers are also able to access up-to-date and detailed 
technical product data sheets. All the antibodies are sold under the Abcam brand 
name and the Company's vision is to build the world's largest online resource of 
high-quality and commercially viable antibodies. Abcam now has an online 
catalogue of over 55,000 products, most of which are antibodies, from over 250 
suppliers and employs 237 staff in its three operating companies.   
  
 
This information is provided by RNS  
  
The company news service from the London Stock Exchange  
  
  END  
  
RDSLQLFBKBBFFBD  
  

---

back to RNS news